MannKind Corp. Is Breaking Out On Study News
MannKind Corp. (MNKD) announced a few minutes ago that the results of two phase I studies demonstrated that investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates... [read full story]
|
RELATED
|
|
Studies demonstrate that investigational cancer vaccines show encouraging immune response rates
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced...
BioMed News: Rockwell Medical, EXACT Sciences, MannKind
Mike Havrilla submits: The BioMedReports.com FDA Calendar service includes a database with over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k,...
Studies Show Early Promise of MannKind s Cancer Immunotherapy Program in Melanoma, Prostate...
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced...
Studies Show Early Promise of MannKind's Cancer Immunotherapy Program in Melanoma, Prostate...
WASHINGTON----Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in...
Related categories
International Editions
English - US | English - UK | Deutsch | Français | Español - España | Português - Portugal | Italiano | Čeština | Русский (Russian) | عربي (Arabic) | 中文（简）(Simplified Chinese) | Español - México | Português - Brasil | 한국어 (Korean) | English - India
